Global Antibody Conjugates Drugs Market 2016-2020

Global Antibody Conjugates Drugs Market 2016-2020

  • March 2016 •
  • 75 pages •
  • Report ID: 3767888 •
  • Format: PDF
About Antibody Drug Conjugates

ADCs, empowered monoclonal antibodies (mAbs), use chemical linkers with labile bonds to attach biologically active substances. ADCs target mAbs with the cancer killing ability of cytotoxic drugs, allowing sensitive discernment between healthy and diseased tissue.
Antibodies are the proteins produced by B-cells (from bone marrow) in the immune system. These proteins attach to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies that attach to different sites of an antigen. mAbs, complex proteins with high molecular weight, are monospecific as they are the clones of a single parent cell. They are of three types, chimeric, humanized, and fully human, and are often used for therapeutic and diagnostic purposes.

Technavio’s analysts forecast the global ADCs market to grow at a CAGR of 41.58% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global ADCs market for the period 2015-2020. To calculate the market size, the report considers revenue generated from the sales of ADCs used to treat cancer.


The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Technavio's report, Global Antibody Drug Conjugates Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendorsoperating in this market.

Key vendors
- F. Hoffmann-La Roche AG
- Seattle Genetics Inc.
- Takeda Pharmaceutical Company


Other prominent vendors
- AbbVie
- AbGenomics
- ADC Therapeutics
- Agensys
- ALMAC Group
- Ambrx
- Astellas Pharma
- AstraZeneca
- Bayer HealthCare
- CARBOGEN AMCIS
- Celldex Therapeutics
- Daiichi Sankyo
- Endo Pharmaceuticals
- Esperance Pharmaceuticals
- Formation Biologics
- Genmab
- GlaxoSmithKline
- Immunogen
- Kairos Therapeutics
- MedImmune
- Mersana Therapeutics
- Novartis
- Oxford Biotherapeutics
- Pfizer
- Stemcentrx
- Synthon Biopharmaceuticals
- Zymeworks

Market driver
- Robust late-stage pipeline
- For a full, detailed list, view our report

Market challenge
- High developmental costs
- For a full, detailed list, view our report

Market trend
- Strategic alliances
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Loading...

We are very sorry, but an error occurred.
Please contact [email protected] if the problem remains.